1. Introduction {#sec1-genes-11-00721}
===============

Testosterone is a universally known hormone which is responsible for the development of primary, as well as secondary male characteristics, such as genitalia, beards and muscle mass \[[@B1-genes-11-00721]\]. Historically, the role of testosterone was thought to be limited to the development of male characteristics and sexual function; however, recently it has come to light that the role of testosterone may be multifarious. Research has reported testosterone to be essential to male health, with some studies showing mortality rates to be as much as 40% higher in individuals with extremely low testosterone levels \[[@B2-genes-11-00721],[@B3-genes-11-00721]\]. Studies conducted over the previous decades have discovered that testosterone has the potential to influence men both physically and psychologically, affecting the overall health of the male population.

Male hypogonadism is defined by The Endocrine Society as the inability to produce physiological levels of testosterone and is clinically defined as an early morning testosterone concentration of 250--300 ng/dL or below \[[@B4-genes-11-00721]\]. Hypogonadism can be present at any phase of life, from fetal development to old age; however, it is known that serum testosterone levels steadily decrease as men age \[[@B5-genes-11-00721],[@B6-genes-11-00721]\] and is symptomized by decreased libido, erectile dysfunction, decreased muscle mass and bone mineral density, all of which were previously dismissed as a natural consequence of aging. Testosterone levels begin to naturally decrease between the ages of 20 and 30 in males, at a rate of about 1.3% per year \[[@B7-genes-11-00721]\], and by the age of 45, about 39% of men have serum testosterone levels below 300 ng/dL \[[@B8-genes-11-00721]\]. An investigation into testosterone tests undertaken by individuals in United Kingdom and the United States, from the years 2000 to 2011, shows that male hypogonadism is quite common, with an excess of 20% of tests displaying a low level of serum testosterone (\< 300 mg/dL). This phenomenon is not only restricted to the elderly, as up to 76% of participants were between the ages of 40 and 64 \[[@B9-genes-11-00721]\].

Increasing awareness of hypogonadism and its association with common conditions such as type II diabetes mellitus, obesity and metabolic syndrome, ultimately gave rise to testosterone replacement therapy (TRT) in an attempt to reverse the effects of hypogonadism. A recent meta-analysis randomized control trial (RCT) reports that TRT can improve quality of life, libido, depression and erectile dysfunction \[[@B10-genes-11-00721]\]; further studies report the positive effects of TRT on obesity, lipid profile and cardiovascular risk factors \[[@B11-genes-11-00721]\]. The safety of testosterone supplement usage has been called into question, with increased incidents of cardiovascular events observed in patients undergoing therapy \[[@B12-genes-11-00721]\]. Two large-scale observational studies have since confirmed increased occurrence of cardiovascular events as a result of TRT \[[@B13-genes-11-00721],[@B14-genes-11-00721]\], leading Health Canada and the US Food and Drug Administration (FDA) to place labels on TRT products in an attempt to warn the public of the potentially adverse cardiological effects of TRT.

Testosterone has also been shown to greatly influence male behavior, particularly aggressive behaviors which can termed as antisocial, while also stimulating generosity when it can serve to increase the male's dominance \[[@B15-genes-11-00721],[@B16-genes-11-00721]\]. Over the past few decades, testosterone has been consistently linked to cognitive decline, particularly in the elderly \[[@B17-genes-11-00721]\]. Results from several epidemiological studies have suggested that testosterone acts as a metabolic hormone in males, as there is a negative correlation between testosterone levels (both free as well as *SHBG* bound) and obesity across all age groups \[[@B18-genes-11-00721],[@B19-genes-11-00721],[@B20-genes-11-00721],[@B21-genes-11-00721]\].

Mendelian randomization provides us with a technique that can uncover causal relationships without the extensive costs incurred by randomized control trials, and is becoming increasingly more viable as data from numerous large genome wide association studies (GWAS) investigating a diverse range of conditions over the past decade are now publicly available. Early Mendelian randomization studies involving testosterone were performed in small samples and were subsequently met with little success \[[@B22-genes-11-00721],[@B23-genes-11-00721],[@B24-genes-11-00721]\]; recent studies that shifted to the use of large-scale GWAS to source associations of variant with exposure and outcome have reported significant findings regarding testosterone levels and the risk of stroke, cardiovascular disease, polycystic ovary syndrome, as well as breast, endometrial and prostate cancer \[[@B25-genes-11-00721],[@B26-genes-11-00721]\].

It is now obvious that the functions of testosterone extend well beyond the sexual domain, especially in men, affecting both physiological and mental aspects of life. Hypogonadism is widespread and inevitable; however, it is difficult to conduct studies to ascertain the full extent of testosterone influence, which has been hypothesized to play a role in a range of common metabolic, immune and psychiatric diseases \[[@B27-genes-11-00721],[@B28-genes-11-00721],[@B29-genes-11-00721],[@B30-genes-11-00721],[@B31-genes-11-00721],[@B32-genes-11-00721],[@B33-genes-11-00721]\].

In this study, we aim to determine the effect of testosterone on previously associated common diseases, namely, type II diabetes (T2D), rheumatoid arthritis (RA), gout, depression, bipolar disorder (BP), schizophrenia (SCZ) and Alzheimer's disorder (AD) \[[@B27-genes-11-00721],[@B28-genes-11-00721],[@B29-genes-11-00721],[@B30-genes-11-00721],[@B31-genes-11-00721],[@B32-genes-11-00721],[@B33-genes-11-00721]\], by conducting a two-sample Mendelian randomization study in an effort to determine whether testosterone could potentially play a causative role in these disorders. To our knowledge, this is the first Mendelian randomization study looking into the relationship between testosterone and common diseases.

2. Materials and Methods {#sec2-genes-11-00721}
========================

2.1. Genetic Instruments (Genetic Associations with Testosterone) {#sec2dot1-genes-11-00721}
-----------------------------------------------------------------

The genetic instruments for testosterone were created using data from the REDUCE study, where 3225 men of European descent between the ages of 50 and 75 years had consented to additional genetic testing \[[@B34-genes-11-00721]\]. The only variants significantly associated with serum testosterone at a genome-wide association level were present at 10q21, 17p13, Xp22, and were henceforth referred to as the *JMJD1C*, *SHBG* and *FAM9B* loci, respectively. Variants from the *FAM9B* locus were not included in our analysis since genetic variants in outcome data did not include the sex chromosomes. The *SHBG*, also known as sex hormone binding globulin, has a mechanistic link to all sex hormones and testosterone is no different, while the *JMJD1C* locus is associated with testosterone levels independent of *SHBG*.

Genetic instruments were created for both *JMJD1C* and *SHBG* loci separately, and a total of 661 and 325 variants were reported for the *JMJD1C* and *SHBG* loci, respectively. The genetic instrument for the *JMJD1C* locus was created based on a single genome-wide significant variant while the instrument for the *SHBG* locus was created using a step-wise selection procedure similar to the one used in a previous Mendelian randomization study \[[@B26-genes-11-00721]\]. In brief, for the *SHBG* locus, from the list of 325 variants, the strongest variant in terms of *p*-value was selected, and all other variants that were in linkage disequilibrium (defined as having an *r*^2^ value of \> 0.40) were removed, after which the process was repeated for the next most significant variant, resulting in a set of variants with low pair-wise correlations.

2.2. Genetic Association with Outcomes {#sec2dot2-genes-11-00721}
--------------------------------------

Genetic association data for the selected outcomes were sourced from the GWAS catalogue. In this study, we investigated the association of the genetic instrument with various outcomes, namely, type 2 diabetes (T2D), gout, rheumatoid arthritis (RA), depression, schizophrenia, bipolar disorder and Alzheimer's disorder. The genetic associations for T2D were extracted from a recently published meta-analysis of GWA studies that comprised approximately 16 million variants and included 62,892 cases along with 596,424 controls of European descent \[[@B35-genes-11-00721]\]. This meta-analysis was comprised of data from DIAGRAM, GERA and UK Biobank data sets.

The second outcome was derived from a study by Tin et al. \[[@B36-genes-11-00721]\], who performed a transancestry meta-analysis of serum urate levels (457,690 individuals) and made a subsequent prediction of gout in a separate cohort of 334,880 individuals from the UK Biobank. For RA, the genetic associations were extracted from a meta-analysis of GWA studies that evaluated approximately 10 million single nucleotide polymorphisms (SNPs), with total sample size \>100,000 individuals (of European and Asian descent) comprising 29,880 and 73,758 cases and controls, respectively \[[@B37-genes-11-00721]\].

For depression, we used the genetic associations from the UK biobank \[[@B38-genes-11-00721]\], which has divided depression into three distinct phenotypes, mainly broad depression, probable major depressive disorder (MDD) and MDD as defined by the International Classification of Diseases (ICD). Here we selected genetic associations for broad depression as the outcome measure, as it most closely related to general depression experienced by most individuals. The UK Biobank depression GWAS was comprised of 322,580 participants. Genetic associations for schizophrenia were extracted from the GWAS published by the schizophrenia working group of the Psychiatric Genomics Consortium (PGC) \[[@B39-genes-11-00721]\], which is the largest GWAS performed on a European population today, comprising 36,989 cases and 113,075 controls.

The genetic associations for bipolar disorder were extracted from a recent GWAS that was published in 2019, comprising 20,352 and 31,358 cases and controls, which was followed up with a separate group of an additional 9412 cases and 137,760 controls. A recently published meta-analysis of Alzheimer's disorder studies comprising 67,614 cases was used to extract genetic associations with Alzheimer's disorder. This meta-analysis combined data from the UK Biobank and International Genomics of Alzheimer's Project (IGAP)

2.3. Statistical Analysis {#sec2dot3-genes-11-00721}
-------------------------

Mendelian randomization is a technique that can be used to determine causal exposure--outcome relationships. Since alleles are randomly assigned at birth, genetic variants that are associated with an increase in exposure can be used to determine whether the said exposure could cause disease, while being completely randomized for confounders such as smoking or education, similar to a randomized control trial.

The genetic associations and outcomes were harmonized before the Mendelian randomization analysis, which was performed separately from the two loci (*SHBG* and *JMJD1C*). The Mendelian randomization analysis was performed using the inverse variance (IVW) method: if the genetic instrument is comprised of a single variant then the resulting causal estimate is simply the ratio of association of variant with outcome and exposure. If the genetic instrument consists of more than one variant, then the causal estimate is calculated by pooling the ratio estimates using an inverse variance meta-analysis.

Mendelian randomization analysis requires that genetic instruments utilized are associated with the outcome of interest only via the exposure, and is not associated with other exposures or confounders. In simple terms, Mendelian randomization requires that the genetic instrument used does not display pleiotropy; a test directional pleiotropy can be performed using the MR-Egger intercept estimate \[[@B40-genes-11-00721]\]. Two-sided *p*-values were reported for all analyses and significant casual estimates were defined as estimates with a *p*-value of \< 0.05. Additional sensitivity analyses were performed using the weighted median method, which is capable of providing a consistent estimate even if up to 50% of the genetic instrument is invalid. All analyses were performed using the Mendelian randomization package in R.

3. Results {#sec3-genes-11-00721}
==========

3.1. Genetic Instruments {#sec3dot1-genes-11-00721}
------------------------

After accounting for linkage disequilibrium, the genetic instrument for the *JMJD1C* locus was comprised of a single SNP (rs10822184), while the *SHBG* locus comprised of 20 variants ([Table 1](#genes-11-00721-t001){ref-type="table"}); however, a different set of variants was used depending on availability in the outcome data set. The exact composition of the genetic instruments and the pairwise correlations of the included variants can be found in the [supplementary files (Figures S1--S3 and Tables S1--S3)](#app1-genes-11-00721){ref-type="app"}.

3.2. Mendelian Randomization of the JMJD1C Locus {#sec3dot2-genes-11-00721}
------------------------------------------------

The results of the Mendelian randomization or the *JMJD1C* locus ([Table 2](#genes-11-00721-t002){ref-type="table"}) showed that genetically predicted testosterone was negatively associated with gout (estimate = −0.757, 95% CI = −1.189, −0.324, *p* = 0.001) ([Figure 1](#genes-11-00721-f001){ref-type="fig"}) and T2D (estimate = −0.262, 95% CI = −0.522, −0.002, *p* = 0.048) ([Figure 2](#genes-11-00721-f002){ref-type="fig"}). Each increase in SD for genetically determined serum testosterone levels was positively associated with RA (estimate = 0.525, 95% CI = 0.083, 0.967, *p* = 0.020) ([Figure 3](#genes-11-00721-f003){ref-type="fig"}). There was no association between genetically predicted testosterone and the following outcomes: Alzheimer disorder, bipolar disorder, schizophrenia and depression. Since the genetic instrument for the *JMJD1C* locus was comprised of only a single variant, it was not possible to conduct the sensitivity analyses (weighted median and MR-Egger methods).

3.3. Mendelian Randomization of the SHBG Locus {#sec3dot3-genes-11-00721}
----------------------------------------------

Results of the Mendelian randomization analysis of predictors of testosterone from the SHBG region ([Table 3](#genes-11-00721-t003){ref-type="table"}) showed that genetically predicted testosterone was positively associated with depression and RA, while negatively associated with T2D. Each SD increase in genetically predicted testosterone was associated with a 1.02-fold increased risk of depression (estimate = 0.021, 95% CI = 0.008, 0.031, *p* = 0.001) ([Figure 4](#genes-11-00721-f004){ref-type="fig"}). During the sensitivity analysis, the weighted median method showed similar results to the IVW analysis (estimate = 0.016, *p* = 0.040), while there was no evidence for pleiotropy (MR-Egger intercept = 0.002, *p* = 0.092). For RA, each SD increase in testosterone resulted in a 1.33-fold increase in the risk of RA (estimate = 0.285, 95% CI = 0.141, 0.429, *p* \< 0.001) ([Figure 5](#genes-11-00721-f005){ref-type="fig"}), which was similar to the estimates from the weighted median method sensitivity analysis (estimate = 0.368, *p* \< 0.001) without any evidence of horizontal pleiotropy (MR-Egger intercept = 0.022, 95% CI = −0.006, 0.049, *p* = 0.120). Each SD increase in testosterone correlated to a 0.887-fold increase in the risk of T2D (estimate = −0.119, 95% CI = −0.203, −0.035, *p* = 0.005) ([Figure 6](#genes-11-00721-f006){ref-type="fig"}), which was mirrored by the weighted median method analysis (estimate = −0.107, 95% CI = −0.219, −0.005, *p* = 0.062), without any horizontal pleiotropy detected (MR-Egger intercept estimate = 0.003, *p* = 0.219). Genetic association of genetically predicted testosterone with SCZ, BP, T2D and AD were null; however, the direction of effect for T2D was in agreement with that of the significant effect found in the *JMJD1C* analysis.

4. Discussion {#sec4-genes-11-00721}
=============

Serum testosterone levels naturally decrease over the course of a man's life or could be reduced as a result of hypogonadism. In this study, we aimed to explore the possible effects of this decrease on common diseases by Mendelian randomization, using genetically predicted testosterone levels derived from two gene regions significantly associated with serum testosterone levels. Mendelian randomization analyses were performed separately on the two instruments; results from the JMJD1C and SHBG loci showed significant associations with three outcomes each. We investigated a total of seven diseases, namely, T2D, SCZ, BP, AD, gout, RA and depression, of which four outcomes displayed significant associations with genetically predicted testosterone levels. Analyses of both loci supported significant associations of genetically predicted testosterone with RA and T2D, while also displaying the same direction of effect.

The results of our study show that an increase in serum testosterone has a protective effect on the risk of developing T2D, with both loci displaying significant results with consistent direction of effect. Existing literature has extensively studied the relationship between serum testosterone and T2D, and found testosterone can directly regulate glucose metabolism \[[@B41-genes-11-00721]\]; additionally, low levels of serum testosterone were also associated with reduced insulin sensitivity \[[@B42-genes-11-00721]\]. Testosterone plays an important role in glucose metabolism as it has been shown to increase expression of insulin receptors as well modify the glucose transporter (GLUT4) \[[@B43-genes-11-00721]\]. Testosterone could also regulate glucose homeostasis and glucose uptake via androgen receptor (AR)-dependent pathways in brain, adipose and pancreatic tissues, as well as AR-independent pathways, for example, by activating the LKB1/AMPK signaling pathway in adipocytes \[[@B44-genes-11-00721]\]. Impairment of the AMPK pathway has been observed in T2D patients, activation of which results in improved uptake of glucose \[[@B45-genes-11-00721]\]. Interestingly, activation of the LKB1/AMPK pathway has been shown to result in greater amyloid-β generation \[[@B46-genes-11-00721]\]. A recent meta-analysis investigating the relationship between low serum testosterone and risk of AD concluded that low serum testosterone was significantly associated with increased risk of AD \[[@B33-genes-11-00721]\]; however, this may be a characteristic of disease progression rather than a causal relationship. Alternatively, LKB1/AMPK activation via testosterone earlier in life could potentially cause the build-up of amyloid-β plaques and cause AD. T2D and AD share a common pathology to some extent, as both diseases display insulin signaling defects and resistance \[[@B47-genes-11-00721]\], while testosterone may play a crucial role in the pathogenesis of both these disorders. Additionally, hyperglycaemia, which could result, has also been shown to reduce serum testosterone levels \[[@B48-genes-11-00721],[@B49-genes-11-00721]\], which indicates that these relationships are not as straight forward as one may think, as elevated glucose levels result in an increase in adipose tissue, which in turn result in a reduction in testosterone production \[[@B50-genes-11-00721]\].

Historically low levels of serum testosterone have been regularly associated with RA \[[@B51-genes-11-00721],[@B52-genes-11-00721]\], and the hypothalamic--pituitary--adrenal axis has been shown to be affected by RA \[[@B53-genes-11-00721]\], potentially leading to patients affected by RA to display aberrant testosterone levels \[[@B54-genes-11-00721]\]. In our analysis, we show that increased serum testosterone increases the risk of developing RA, and a recent study investigating the future risk of developing RA in men concluded that low serum testosterone is associated with a rheumatoid factor (RF) negative prediction \[[@B29-genes-11-00721]\], suggesting the low levels of testosterone may provide protection against development of RA.

Hypogonadism has been linked to depression in males \[[@B55-genes-11-00721],[@B56-genes-11-00721]\], while testosterone has potential antidepressive properties \[[@B57-genes-11-00721]\]; our results surprisingly suggest that increased testosterone may actually slightly increase the risk of depression.

5. Conclusions {#sec5-genes-11-00721}
==============

In conclusion, our Mendelian randomization study assessed the effect of testosterone on the risk of several common diseases. We report that testosterone has a protective effect on the risk of T2D and gout, while having adverse effects on depression and RA. There were, however, a few limitations of our study, first and foremost being that the genetic instruments used in our Mendelian randomization were sourced from variant testosterone associations measured in men; therefore, our findings are largely relevant to common diseases in men. Another limitation of our study was the use of variants in the SHBG region to genetically predict testosterone. SHBG can bind to free testosterone, thereby affecting the concentrations of testosterone in the blood; though SHBG can be linked to testosterone levels mechanistically, it is difficult to distinguish between the effects of testosterone from that of SHBG.

Our findings, along with previous Mendelian randomization studies on the effect of testosterone on obesity and adverse cardiac events, highlight the importance of testosterone in overall health and well-being, particularly in males. The results of our study show that further research into the effects of testosterone is required, especially in light of the increasing utilization of testosterone therapy.

The following are available online at <https://www.mdpi.com/2073-4425/11/7/721/s1>. Figure S1: LD matrix---depression, *SHBG* instrument locus; Figure S2: LD matrix---RA instrument, *SHBG* locus; Figure S3: LD matrix---T2D instrument, *SHBG* locus; Table S1: Depression, *SHBG* instrument locus; Table S2: RA instrument, *SHBG* locus; Table S3: T2D instrument, *SHBG* locus.

###### 

Click here for additional data file.
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genes-11-00721-t001_Table 1

###### 

Detailed composition of the genetic variants used in the Mendelian randomization analysis.

  ------------------------ -------------- ---------- --------------- -------------------- -------- --------
  ***JMJD1C*** **Locus**                                                                           
  **SNP**                  **Position**   **Beta**   **Beta (se)**   ***p*** **-Value**   **EA**   **OA**
  rs10822184               65007159       −0.058     0.01            1.12 × 10^−8^        T        C
  ***SHBG*** **Locus**                                                                             
  **SNP**                  **Position**   **Beta**   **Beta (se)**   ***p*** **-Value**   **EA**   **OA**
  rs727428                 7478517        −0.073     0.01            1.26 × 10^−12^       T        C
  rs1799941                7474148        0.082      0.012           1.39 × 10^−12^       A        G
  rs17806566               7292887        −0.168     0.03            2.61 × 10^−8^        C        T
  rs9913778                7474626        −0.106     0.019           3.05 × 10^−8^        T        C
  rs9900162                7387788        −0.07      0.013           6.13 × 10^−8^        G        A
  rs35894069               7335900        0.054      0.011           5.74 × 10^−7^        A        G
  rs9908275                7367048        −0.065     0.014           1.59 × 10^−6^        T        C
  rs4511593                7396260        0.051      0.011           1.73 × 10^−6^        C        T
  rs55784804               7477185        −0.075     0.018           2.25 × 10^−5^        T        G
  rs3853818                7287026        −0.044     0.01            2.36 × 10^−5^        T        C
  rs12944954               7425855        −0.181     0.043           2.88 × 10^−5^        G        A
  rs55894190               7323962        −0.042     0.01            6.90 × 10^−5^        C        T
  rs8069501                7335692        −0.087     0.023           1.52 × 10^−4^        G        A
  rs858517                 7474996        −0.091     0.026           4.44 × 10^−4^        C        T
  rs2955611                7490299        −0.053     0.016           9.08 × 10^−4^        C        A
  rs12942088               7423503        −0.033     0.01            1.59 × 10^−3^        C        T
  rs2302762                7299585        −0.034     0.011           3.06 × 10^−3^        T        C
  rs12936934               7441490        −0.036     0.014           9.74 × 10^−3^        T        C
  rs4968211                7399786        −0.063     0.026           1.4 × 10^−2^         A        G
  rs4796305                7276779        −0.037     0.019           4.6 × 10^−2^         G        T
  ------------------------ -------------- ---------- --------------- -------------------- -------- --------

genes-11-00721-t002_Table 2

###### 

Mendelian Randomization (MR) using variants from the *JMJD1C* Locus---Inverse Variance Weighted (IVW) Method.

  Outcome                OR      Estimate (se)    *p*-Value
  ---------------------- ------- ---------------- -----------
  Alzheimer's Disorder   0.875   −0.133 (0.145)   0.359
  Bipolar Disorder       1.402   0.338 (0.234)    0.149
  Schizophrenia          1.132   0.124 (0.182)    0.496
  Depression             0.984   −0.016 (0.020)   0.437
  Rheumatoid Arthritis   1.690   0.525 (0.226)    0.020
  Gout                   0.469   −0.757 (0.221)   0.001
  Type 2 Diabetes        0.769   −0.262 (0.133)   0.048

genes-11-00721-t003_Table 3

###### 

Mendelian Randomization (MR) using variants from the *SHBG* Locus---Inverse Variance Weighted (IVW) Method.

  ----------------------------------------------------------------------------------
  Outcome                OR      Beta (se)        *p*-Value   MR-Egger Intercept\
                                                              Estimate (*p*-Value)
  ---------------------- ------- ---------------- ----------- ----------------------
  Alzheimer's Disorder   0.998   −0.002 (0.029)   0.935       0.013 (0.015)

  Bipolar Disorder       0.991   −0.009 (0.085)   0.920       0.007 (0.664)

  Schizophrenia          1.038   0.038 (0.053)    0.176       −0.004 (0.672)

  Depression             1.02    0.020 (0.006)    0.001       0.002 (0.092)

  Rheumatoid Arthritis   1.329   0.285 (0.060)    \<0.001     0.022 (0.120)

  Gout                   0.971   −0.029 (0.064)   0.649       0.005 (0.683)

  Type 2 Diabetes        0.887   −0.119 (0.030)   0.003       −0.027 (0.607)
  ----------------------------------------------------------------------------------
